Good morning!
It’s now hard to believe that Aperture Health, Inc. (APRE) used to keep a pretty low profile, going months without a single share moving.
APRE is now moving MILLIONS of shares a session as the market clues into what this company’s new home intravenous treatment business means for its bottom line.
For the first time in living memory, there’s enough skin in the APRE game for traders to actually make real money.
Chart Analysis:
95% of all APRE volume from the last year moved in the last 5 days. That’s not just a volume spike…it’s a chart-changing event.
The accumulation/distribution line dipped as traders sensibly lightened up after APRE’s most recent 4-bag swing, but now they’re buying again!
MACD has been leading signal back upward for almost a month now. Slowly but surely, momentum is getting back behind APRE.
RSI is near the 30-point “oversold” lin where it was right before APRE hopped 70% from $0.33 to $0.56 a few weeks ago.
APRE is now 22% below even the 10-day trend that it had previously tracked extremely closely. Some “reversion to mean” would be nice!
APRE is definitely giving us all something NEW to ponder!
A few weeks ago APRE closed a strategic acquisition, becoming a significant player in the home healthcare industry in the process — and shortly thereafter, the chart went crazy!
Part of the excitement is that traders have learned to appreciate that APRE delivers home intravenous therapy – roughly a $10 BILLION slice of the national medical spend. (Read more)
With a public float of maybe 5 million APRE shares trading under $0.30 apiece, grabbing an infinitesimal 0.01% of that $10 billion opportunity would cover the entire current market cap! (Read more)
APRE is already collecting partners to consolidate its reach and build market share: medical equipment distributors, even veterinarians are signing up.
But what makes APRE such a golden ticket for traders looking to make a buck in the healthcare system is simplicity itself.
Staying in a hospital to get your drip costs maybe $2,000 a night. Getting a “home infusion” costs you — and the insurance company — maybe $200 tops. (Read more)
The referrals are already coming in from just about everyone: doctors, hospital case workers and even the insurers themselves are happy to get sick people to check out of the hospital and hook up to APRE’s machines in the comfort of home. (Read more)
Bottom Line: APRE just cleared up its reporting status and became a fully documented member of the pink sheets! (Read more)
That was evidently the signal, because APRE volume soared from effectively zero that very day, and has kept ramping up ever since.
The smallest, dinkiest, least impressive candlestick this high-stepping beauty has printed in the last 5 days: 20%.
Want to see where APRE takes us today? Load it up and find out!
See you in the winners’ circle!
Beacon Equity Group
Super Nova members raked in over a QUARTER MILLION DOLLARS recently.Are you ready to bring home some of that cash?
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. BeaconEquity.com is a wholly-owned subsidiary of BlueWave Advisors, LLC. BlueWave Advisors is currently being compensated thirty five thousand dollars from Stellar Media Group (a non-controlling third-party shareholder) for APRE advertising and promotion. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. BWA does not hold a postion in the covered company.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
